Jonas Graf
Overview
Explore the profile of Jonas Graf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akmatov M, Graf J, Kohring C, Ellenberger D, Batzing J, Tremlett H, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2452652.
PMID: 39729316
Importance: A growing body of literature suggests the presence of a prodromal period with nonspecific signs and symptoms before onset of multiple sclerosis (MS). Objective: To systematically assess diseases and...
2.
Graf J, Akmatov M, Meuth S, Tremlett H, Holstiege J
JAMA Neurol
. 2024 Sep;
81(10):1100-1102.
PMID: 39250144
No abstract available.
3.
Graf J, Weise M, Guthoff T, Balloff C, Gasis M, Link H, et al.
Front Immunol
. 2024 Sep;
15:1431394.
PMID: 39224585
Objectives: The pathophysiology of multiple sclerosis (MS) involves inflammatory neurodegeneration in the brainstem, cerebellum, and retina. The clinical relevance of oculomotor involvement in MS, however, remains uncertain. Methods: In this...
4.
Graf J, Ng H, Zhu F, Zhao Y, Wijnands J, Evans C, et al.
Lancet Reg Health Am
. 2024 Jan;
29:100667.
PMID: 38269206
Background: Much remains unknown surrounding the disease-modifying drugs (DMDs) used to treat multiple sclerosis and infection-related healthcare use in the 'real-world' setting. We examined if DMD exposure was associated with...
5.
Graf J, Ng H, Zhu F, Zhao Y, Wijnands J, Evans C, et al.
Sci Rep
. 2023 Dec;
13(1):21235.
PMID: 38040796
Little is known about disease-modifying drug (DMD) initiation by immigrants with multiple sclerosis (MS) in countries with universal health coverage. We assessed the association between immigration status and DMD use...
6.
Graf J, Ng H, Zhu F, Zhao Y, Wijnands J, Evans C, et al.
Mult Scler
. 2022 Mar;
28(11):1825-1828.
PMID: 35232298
We described emergency department (ED) visits (all visits and infection-related) by persons with multiple sclerosis (MS) in British Columbia, Canada (1 April 2012 to 31 December 2017). We identified 15,350...
7.
Balloff C, Penner I, Ma M, Georgiades I, Scala L, Troullinakis N, et al.
Brain Stimul
. 2022 Feb;
15(2):403-413.
PMID: 35182811
Background: Cortical reorganization and plasticity may compensate for structural damage in Multiple Sclerosis (MS). It is important to establish sensitive methods to measure these compensatory mechanisms, as they may be...
8.
Ng H, Graf J, Zhu F, Kingwell E, Aktas O, Albrecht P, et al.
Front Immunol
. 2022 Jan;
12:794075.
PMID: 35095869
Background: Evidence regarding the efficacy or effectiveness of the disease-modifying drugs (DMDs) in the older multiple sclerosis (MS) population is scarce. This has contributed to a lack of evidence-based treatment...
9.
Graf J, Leussink V, Soncin G, Lepka K, Meinl I, Kumpfel T, et al.
Brain Commun
. 2021 Nov;
3(4):fcab229.
PMID: 34755108
The objective of this study was to investigate confirmed progression independent of relapse activity in relapsing-remitting multiple sclerosis patients under long-term natalizumab treatment. We performed a retrospective, cross-sectional study of...
10.
Ingwersen J, Graf J, Kluge J, Weise M, Dietrich M, Lee J, et al.
Neurol Neuroimmunol Neuroinflamm
. 2021 Oct;
9(1).
PMID: 34667130
Background And Objectives: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease primarily affecting the peripheral nervous system. However, several noncontrolled studies have suggested concomitant inflammatory CNS demyelination similar to...